Loading stock data…
A
$132.80-2.68 (-1.98%)
Market OpenUpdated 1:27 PM EDT
Agilent Technologies, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
A in the Healthcare sector is trading at $132.80. Wall Street consensus targets $161.00 (16 analysts), implying a +21.2% move over the next 12 months. The stock is currently 17% below its 52-week high of $160.27, remaining 2.2% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +21.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.83B↑ | $1.80B↓ | $1.86B↑ | $1.74B↑ | $1.67B |
| Gross Profit | $990.00M↑ | $946.00M↓ | $990.00M↑ | $888.00M↑ | $866.00M |
| Operating Income | $399.00M↑ | $353.00M↓ | $443.00M↑ | $360.00M↑ | $300.00M |
| Net Income | $339.00M↑ | $305.00M↓ | $434.00M↑ | $336.00M↑ | $215.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and App...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.77%
ROE
Elite ROE. Management converts capital into profit efficiently.
15.56%
Volume
Today's trading volume
377,532
Recent News
Is IQVIA Holdings Stock Outperforming the Dow?
IQVIA Holdings has outperformed the Dow over the past year, and analysts are highly optimistic about the stock’s prospects.
Here's Why We Think Agilent Technologies (NYSE:A) Might Deserve Your Attention Today
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Agilent Technologies (A) Is Up 18.6% After AI Pact With OpenAI And Raised 2026 Guidance - Has The Bull Case Changed?
In late May and early June 2026, Agilent Technologies reported higher quarterly sales and earnings, raised its full-year 2026 revenue guidance to US$7.39–7.49 billion, and announced multiple new product launches across diagnostics and analytical instrumentation. Agilent also revealed an enterprise-wide artificial intelligence collaboration with OpenAI and Boston Consulting Group, aiming to embed advanced AI into its instruments, software, and customer workflows to enhance product...
Agilent Technologies (A) Declined in Q1 Amid QIAGEN Acquisition Speculation
Impax Asset Management, an investment management firm based in London, specializing in sustainable investing, released its first-quarter 2026 investor letter for its “Impax Global Environmental Markets Fund”. A copy of the letter is available to download here. The Fund stood resilient in the quarter by outperforming its primary benchmark, the MSCI ACWI index. The stock […]
The 5 Most Interesting Analyst Questions From Agilent’s Q1 Earnings Call
Agilent’s second quarter saw a positive market reaction, underpinned by broad-based revenue growth and notable operating margin expansion. Management credited the quarter’s outperformance to strong demand across key end markets, robust instrument sales, and the benefits of its Ignite operating system. CEO Padraig McDonnell highlighted that “replacement site momentum, innovation-led share gains, and improving operational execution” were central to Agilent’s results, while the company’s strategic